# **Product Portfolio**and Performance

Consistency, diversification, investment discipline and steady deployment pace, regardless of the stage of the cycle, are the pillars of AltamarCAM's long-term focus

With this approach, AltamarCAM builds its investment programs alongside international managers with a proven track record





## Investment philosophy and value generation

AltamarCAM's investment programs are based on the mainstays of a long-term perspective, capital preservation and the quest for Alpha.

The funds managed by AltamarCAM Partners have applied this investment philosophy since the first program that was launched.

In our search for ways to protect our investments we are constantly asking ourselves: Why do we think we will recover our capital? What could go wrong? How can we eliminate the risks of this investment?

This process is applied to all the firm's investment areas, with our investors

benefiting from the broad and indepth knowledge provided by our global multi-asset platform. It's not a case of having a lot of investments but rather of building a robust investment portfolio with low correlation. We deploy our resources where there is value

Our investment teams work on Primary, Secondary and Co-Investment opportunities, giving AltamarCAM a competitive edge by developing long-term, value-added relationships with fund managers. Our flexible investment approach, global presence and multiple asset classes give us privileged and preferential access to the best investment opportunities.

#### About u

Message from
 Our managemen

2. Client Solutions and Services Investor Relations Tailored Solutions

 Product Portfolio and Performance

> 3. Investment Businesses

4.
Advisory and Distribution Businesses

Investing in

## **Funds Strategy**

AltamarCAM is a Pan-European private assets investment platform focused on providing investment solutions to clients. The firm is specialized in six different assets classes: Private Equity, Venture Capital, Life Sciences, Real Estate, Infrastructure and Private Credit

AltamarCAM has extensive knowledge of the international private assets market and manages a range of strategies across different asset classes

Funds	Vintage	Investment strategy	Market Segment	% Area
Private Equity (Buyouts/	Growth)			
CAM II	2000	Global Buyout & Growth	Mid to Large Market	Europe c. 50% North America c.50%
CAM III	2004	Global Buyout & Growth	Mid to Large Market	Europe c. 50% North America c.40% Asia / RoW c.5%
Altamar Buyout Europe	2005	European and Global Buyouts	Large & Mid Market	Europe 85% USA / RoW 15%
Altamar Buyout Global II & III	2007	Global Buyout	Large, & Mid Cap Market	Europe 60% USA / RoW 40%
CAM Evergreen	2005 - 2021	Global Buyout & Growth	Large, & Small Cap Market	Europe c.75% North America c.20% Asia / RoW c.5%
CAM IV	2007	Global Buyout & Growth	Small to Large Market	Global
Altamar Secondary Opportunities IV – ACP S1	2010	Global Buyouts (Secondary Market). Secondaries	Secondaries	
Altamar V Private Equity Program	2011	Global Buyouts /Growth Emerging Markets/Special Opportunities	Upper - Mid - Low Mid Market	Europe 30-40% USA 30-40% Asia / Latam 10%-15% Special Opp. 15%-20% Sec / Co-Inv. up to 20%
CAM V	2013	Global Buyout	Large & Mid Market	Europe c.50% North America c.30% Asia / RoW c.20%
Altamar VI Emerging Markets	2013	Buyouts / Emerging Market Growth	Upper - Mid - Low Middle Market	Asia 50-60% Latam 40-50%



2014	Global Buyouts (Secondary Market). Secondaries	Secondaries	
2014	Buyout Global / Emerging Markets/ Special Opportunities	Upper - Mid - Low Middle Market	Europe 30-40% USA 30-40% Asia / Latam 10%-15% Special Opp. 15%-20% Sec / Co-Inv. Up to 30%
2015	DACH Buyout (Small to Mid Market)	Small to Mid Market	Europe / DACH 100%
2017	Buyout Global (Secondary Market)	Secondaries	
2018	Global Buyout	Upper-Mid- Low Middle Market	Europe 30-40% USA 30-40% Asia / Latam 10%-15% Special Opp. 15%-20% Sec / Co-Inv. Up to 30%
2020	Global Buyout (Middle Market)	Middle Market	Europe c. 40-60% North America c.30-40% Asia up tp 20%
2020	Global Secondaries	Large, Mid & Small Market	
2008	European VC	Small Market	Europe c.95% North America c.5%
2016	Venture Capital	Late Stage / Growth	Western Europe, USA, Emerging Markets
2018	Sequoia Global Growth III		
2018	Venture Capital	Late Stage / Growth	Western Europe, USA, Emerging Markets
2021	Venture Capital	Late Stage / Growth	Western Europe, USA, Emerging Markets
2006	Global Life Science VC	Small Market	Europe c.25% North America c.75%
2017	Life Sciences	Multi Stage	Spain with possible investments in other countries
2018	Global Life Science VC & Growth	Small Market	Europe c.65% North America c.25% Asia / RoW c.10%
	2014 2015 2017 2018 2020 2020 2020 2020 2018 2018 2018	(Secondary Market). Secondaries  2014 Buyout Global / Emerging Markets/ Special Opportunities  2015 DACH Buyout (Small to Mid Market)  2017 Buyout Global (Secondary Market)  2018 Global Buyout (Middle Market)  2020 Global Secondaries  2020 Global Secondaries  2020 Furopean VC  2016 Venture Capital  2018 Sequoia Global Growth III  2018 Venture Capital  2021 Venture Capital  2021 Venture Capital  2031 Venture Capital  2042 Global Life Science VC  2053 Global Life Science VC  2064 Global Life Science VC  2075 Life Science VC & Global Life Science VC & Global Life Science VC & Global Life Science VC	(Secondary Market). Secondaries  2014 Buyout Global / Emerging Markets/ Special Opportunities  2015 DACH Buyout (Small to Mid Market)  2017 Buyout Global (Secondary Market)  2018 Global Buyout Upper-Mid-Low Middle Market  2020 Global Buyout (Middle Market)  2020 Global Buyout Market  2020 Global Secondaries  2020 Global Secondaries  2020 Global Secondaries  2020 Global Large, Mid & Small Market  2020 Global Large, Mid & Small Market  2020 Venture Capital Late Stage / Growth III  2018 Venture Capital Late Stage / Growth  2021 Venture Capital Late Stage / Growth  2021 Venture Capital Late Stage / Growth  2031 Venture Capital Late Stage / Growth  2042 Venture Capital Late Stage / Growth  2053 Secondaries Small Market  2064 Global Life Science VC  2075 Life Sciences Multi Stage  2076 Global Life Science Small Market  2077 Life Science Small Market  2078 Small Market  2088 Small Market

About us

Message from

2. Client Solutions and Services Investor Relations Tailored Solutions

 Product Portfolio and Performance

3. Investment Businesses

4. Advisory and Distribution Businesses

Investing in the future

#### 2. Client Solutions and Services

### **Real Assets**

2021	Real Assets (Infra&Real Estate) - co-investments	Large, Mid & Small Market	Europe / USA with possible investment in other countries
2007	Private Equity Real Estate Global	Large, Mid & Small Market	Europe 40-70% USA 10-30% / Asia 10-30%
2013	Private Equity Real Estate Global	Upper - Mid - Low Middle Market	Global
2017	Private Equity Real Estate Global	Upper - Mid - Low Middle Market	Global
2021	Private Equity Real Estate Global	Upper - Mid - Low Middle Market	Global
2012	Global Infrastructure		Global
2015	Global Infrastructure	Large, Mid & Small Market	OECD
2019	Global Infrastructure	Large, Mid & Small Market	OECD
2021	Global Infrastructure		Global
2017	Senior Loans / Direct Lending	Large Corps. / Mid Market	Europe 70-100% USA 0-30%
2021	Direct Lending / Return Enhancing	Large Corps. / Mid Market	Europe 40-50% USA 40-50% Asia 0-10%
2021	Direct Lending / Return Enhancing	Large Corps. / Mid Market	Europe 40-50% USA 40-50% Asia 0-10%
	2007 2013 2017 2021 2012 2015 2019 2021 2017 2021	(Infra&Real Estate) - co-investments  2007 Private Equity Real Estate Global  2013 Private Equity Real Estate Global  2017 Private Equity Real Estate Global  2021 Private Equity Real Estate Global  2021 Private Equity Real Estate Global  2012 Global Infrastructure  2015 Global Infrastructure  2019 Global Infrastructure  2021 Global Infrastructure  2021 Global Infrastructure  2021 Direct Lending / Return Enhancing  2021 Direct Lending / Return  2021 Direct Lending / Return	(Infra&Real Estate) - co-investments  2007 Private Equity Real Estate Global  2013 Private Equity Real Estate Global  2017 Private Equity Real Estate Global  2017 Private Equity Real Estate Global  2017 Private Equity Real Estate Global  2021 Private Equity Real Estate Global  2021 Private Equity Real Estate Global  2031 Private Equity Real Estate Global  2041 Infrastructure  2053 Global Large, Mid & Small Market  2054 Global Large, Mid & Small Market  2065 Global Large, Mid & Small Market  2076 Global Large, Mid & Small Market  2077 Global Large Corps. / Mid Market  2078 Direct Lending Large Corps. / Mid Market  2079 Direct Lending Large Corps. / Mid Market  2070 Direct Lending Large Corps. / Mid Market  2071 Direct Lending Large Corps. / Mid Market  2071 Direct Lending Large Corps. / Mid Market





Message from
 Our management

#### 2. Client Solutions and Services Investor Relations

Tailored Solutions

 Product Portfolio and Performance

3. Investment Businesses

4. Advisory and Distribution Businesses

the future



## **Funds Performance**

Funds	Vintage	Current Valuation (1)	Distributed to limited partners <sup>(2)</sup>
Private Equity (Buyouts/Growth)			
CAM II	2000	1.5x	146%
CAM III	2004	1.5x	139%
Altamar Buyout Europa	2005	1.8x	179%
Altamar Buyout Global II & III	2007	2.3x - 2.1x	222% / 206%
CAM Evergreen	2005 - 2021	2.4x	55%
CAM IV	2007	1.9x	166%
Altamar Secondary Opportunities IV	2010	2.0x	195%
Altamar V Private Equity Program	2011	2.2x	146%
CAM V	2013	1.9x	85%
Altamar VI Emerging Markets (3)	2013	1.7x	50%
Altamar Secondary Opportunities VII & VII BP	2014	1.8x - 1.6x	121% / 118%
Altamar Private Equity Program VIII & VIII BP	2014	2.0x - 2.0x	38% / 37%
German Access Fund	2015	1.4x	34%
Altamar Global Secondaries IX (4)	2017	2.0x	73%
Altamar X Global Private Equity Program (4)	2018	1.8x	0%
Altamar X - Global Buyout Midmarket (3) (4)	2018	1.8x	0%
CAM VI	2020	1.3x	0%
ACP Secondaries 4 FCR (4)	2020	1.5x	0%
Venture Capital			
CAM Venture Capital Europe Plus	2008	2.8x	155%
Galdana Ventures I (4)	2016	2.3x	9%
Galdana Ventures II FCR (4) Galdana Ventures II RAIF (3) (4)	2018	1.7x 1.7x	0% 0%
Galdana SPV I RAIF (4)	2018	2.1x	5%
Galdana Ventures III FCR Galdana Ventures III RAIF (3) (4)	2021	1.0x 1.0x	0% 0%
Life Sciences			
CAM Life Sciences	2006	1.9x	146%
Alta Life Sciences Spain I (6)	2017	1.0x	0%
CAM HCO	2018	1.6x	3%



	Current		
Vintage	Valuation (1)	to limited partners <sup>(2)</sup>	Yield 2021 (5)
2008	1.6x - 1.7x	125% / 133%	
2013	1.4x	51%	
2017	1.20x	0%	
2021	0.9x	0%	
2012	1.3×	60%	3%
2016	1.3×	19%	3%
2019	1.1x	3%	3.6%
2022	n.a.	n.a.	n.a.
2017	1.1x	16%	
2021	n.a.	n.a.	
2021	1.0x	n.a.	
	2013 2017 2021 2012 2016 2019 2022 2017 2021	2013 1.4x 2017 1.20x 2021 0.9x  2012 1.3x 2016 1.3x  2019 1.1x  2022 n.a.  2017 1.1x 2021 n.a.	2013 1.4x 51% 2017 1.20x 0% 2021 0.9x 0%  2012 1.3x 60% 2016 1.3x 19%  2019 1.1x 3%  2022 n.a. n.a.  2017 1.1x 16% 2021 n.a. n.a.

Past performance is not necessarily indicative of future results since current economic conditions are not comparable to those that existed previously and may not be repeated in the future.

Note: Mature funds include those in the distribution period; young funds include those that have not begun making distributions and its commitments in underlying funds are over 75%; new funds include those that are in investing period with commitments in underlying funds below 75%. The Private Debt Fund is considered new since it takes into account only the Direct Lending allocation of its portfolio.

- 1. Last available valuation published as of March 31, 2022 (4Q2021).
- 2. Distributed to investors to current date.
- 3. Funds denominated in \$.
- 4. Valuation relative to Institutional Classes.
- 5. Annual yield expressed as percentage of the capital drawdown by investors weighted by time. 2021 Yield distributed to investors in January 2022.
- 6. Alta Life Science Spain I is a direct fund.

About u

Message from
 our management

2. Client Solutions and Services Investor Relations Tailored Solutions

- Product Portfolio and Performance
  - 3. Investment Businesses
  - 4.
    Advisory and
    Distribution
    Businesses

Investing in the future